[Diabetes-Talk] Fwd: Recent FDA approvals you should know about!

[gary Melconian]

Thanks for the info.


On August 25, 2022 11:20:39 AM Patricia Maddix via Diabetes-Talk 
<diabetes-talk at nfbnet.org> wrote:

> See below the forwarded message regarding four of the diabetes related 
> devices that have received FDA approval in just the last eight months. 
> Things in the diabetes field are moving at lightning speed and it is very 
> exciting.
> Patricia
>
>
>
> Sent from my iPhone
>
> Begin forwarded message:
>
>> From: "Sanjoy Dutta, Ph.D., Chief Scientific Officer, JDRF" 
>> <Communications at content.jdrf.org>
>> Date: August 25, 2022 at 10:48:16 AM PDT
>> To: pmaddix at comcast.net
>> Subject: Recent FDA approvals you should know about!
>> Reply-To: "Sanjoy Dutta, Ph.D., Chief Scientific Officer, JDRF" 
>> <reply-fec5177375620c7b-664_HTML-14380484-514009018-25009 at content.jdrf.org>
>> 
>> 
>> 
>> 
>> 
>> 
>> 
>> Hey there JDRF Community,
>> 
>> We’ve been making incredible progress in our research for type 1 diabetes 
>> (T1D) treatment and cures, and today we’re sharing a roundup of exciting 
>> recent U.S. Food and Drug Administration (FDA) decisions and what they mean 
>> for our community. When a therapy receives FDA authorization, it is the 
>> culmination of years of work—from an initial idea to securing funding, 
>> conducting research and clinical trials, and applying for authorization—so 
>> we want to celebrate these approvals with you, as these advances will help 
>> improve the lives of people with T1D, and thank you for all you do to 
>> advance T1D research and advocacy through JDRF. Only a select few receive 
>> FDA authorizations—that makes it all the more special!
>> 
>> Thanks to dedicated supporters like you, JDRF is able to fund 
>> groundbreaking studies and the development of new therapies and 
>> technologies that improve the lives of individuals with T1D, no matter 
>> their age or race or ethnicity. We’re grateful to have you moving our work 
>> forward and moving us closer to a world without this disease.
>> 
>> Without further ado, here’s the good news for our community coming out of 
>> the FDA:​
>> 
>> 
>> 
>> A Fourth Artificial Pancreas System
>> The Insulet Omnipod​ 5® is the world’s first tubeless, wearable artificial 
>> pancreas system authorized by the FDA for individuals ages 2 and older. A 
>> group of JDRF-funded researchers created an algorithm, which was eventually 
>> licensed by Insulet Corporation that led to the development of Omnipod 5. 
>> JDRF started the Artificial Pancreas Project over 15 years ago to ensure 
>> people with T1D have better, more innovative ways to manage their T1D until 
>> there are cures.
>> 
>> 
>> 
>> Bolus Insulin Dose from Your Smartphone
>> This past spring, Tandem Diabetes announced the FDA clearance of bolus 
>> insulin dosing from their t:connect® mobile app. This means individuals 
>> with the Tandem t:slim X2™ pump will be able to administer their bolus 
>> remotely from their smartphone—a game changer for those who keep their 
>> insulin pump in hard-to-reach places. Throughout the years, JDRF has 
>> tirelessly supported research to develop better therapies that make it 
>> easier for people to manage their T1D.
>> 
>> 
>> 
>> New Continuous Glucose Monitoring Technology
>> In May, the FDA cleared the Abbott FreeStyle Libre® 3 continuous glucose 
>> monitor (CGM) for people ages 4 and up—adding another option for personal 
>> monitoring devices. CGM technology has revolutionized the treatment and 
>> management of T1D. JDRF has played a pivotal role in the development of CGM 
>> technology—including funding a landmark study in 2008 that demonstrated its 
>> benefits.
>> 
>> 
>> 
>> Advances in Long-Term Implantable CGM
>> Early this year, the FDA approved Senseonics Eversense® E3, the first 
>> long-term implantable CGM system with new enhancements that extends its use 
>> for up to 6 months. This approval gives people with T1D another way to reap 
>> the benefits of CGM technology. JDRF funded the development of an early 
>> Senseonics prototype, which later advanced into the Eversense technology we 
>> know today!
>> 
>> 
>> 
>> 
>> JDRF will continue to monitor the field and push for meaningful 
>> technological advancements—and we won’t ever stop fighting for 
>> affordability, choice, coverage, and cures on our path to a world without T1D.
>> 
>> If you’re able to make a donation today, you can help fund the next 
>> breakthrough in treatments and cures.
>> 
>> Thank you for all you do,
>> 
>> Sanjoy Dutta, Ph.D.
>> Chief Scientific Officer, JDRF
>> 
>> 
>> Donate
>> 
>> 
>> 
>> 						
>> 
>> JDRF
>> 200 Vesey Street, 28th Floor, New York, NY 10281
>> jdrf.org   |   communications at jdrf.org  |    (800) 533-2873
>> 
>> We are a nonprofit 501(c)(3) organization; Copyright 2022. All rights reserved.
>> Unsubscribe    View My Preferences    View as Webpage
>> 
>> 
> _______________________________________________
> Diabetes-Talk mailing list
> Diabetes-Talk at nfbnet.org
> http://nfbnet.org/mailman/listinfo/diabetes-talk_nfbnet.org
> To unsubscribe, change your list options or get your account info for 
> Diabetes-Talk:
> http://nfbnet.org/mailman/options/diabetes-talk_nfbnet.org/gmelconian619%40gmail.com